ABSTRACT
To evaluate the impact of electroconvulsive therapy on arterial blood pressure, heart rate, heart rate variability, and the occurrence of ischemia or arrhythmias, 38 (18 men) depressive patients free from systemic diseases, 50 to 83 years old (mean: 64.7 ± 8.6) underwent electroconvulsive therapy. All patients were studied with simultaneous 24-h ambulatory blood pressure and Holter monitoring, starting 18 h before and continuing for 3 h after electroconvulsive therapy. Blood pressure, heart rate, heart rate variability, arrhythmias, and ischemic episodes were recorded. Before each session of electroconvulsive therapy, blood pressure and heart rate were in the normal range; supraventricular ectopic beats occurred in all patients and ventricular ectopic beats in 27/38; 2 patients had non-sustained ventricular tachycardia. After shock, systolic, mean and diastolic blood pressure increased 29, 25, and 24 percent (P < 0.001), respectively, and returned to baseline values within 1 h. Maximum, mean and minimum heart rate increased 56, 52, and 49 percent (P < 0.001), respectively, followed by a significant decrease within 5 min; heart rate gradually increased again thereafter and remained elevated for 1 h. Analysis of heart rate variability showed increased sympathetic activity during shock with a decrease in both sympathetic and parasympathetic drive afterwards. No serious adverse effects occurred; electroconvulsive therapy did not trigger any malignant arrhythmias or ischemia. In middle-aged and elderly people free from systemic diseases, electroconvulsive therapy caused transitory increases in blood pressure and heart rate and a decrease in heart rate variability but these changes were not associated with serious adverse clinical events.
Subject(s)
Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Blood Pressure/physiology , Electroconvulsive Therapy/methods , Heart Rate/physiology , Analysis of Variance , Blood Pressure Monitoring, Ambulatory , Electrocardiography, Ambulatory , Electroconvulsive Therapy/adverse effectsABSTRACT
Este estudo com a nefazodona, um novo inibidor seletivo de recaptaçäo de serotonina(ISRS), tem o objetivo maior de mostrar o perfil de interaçöes medicamentosas, droga com droga, assim como com o CYP-450, mostrando os principais efeitos colaterais e açöes terapêuticas principais
Subject(s)
Humans , Male , Female , Cytochrome P-450 Enzyme System/drug effects , Cytochrome P-450 Enzyme System/therapeutic use , Depression/diet therapy , Depression/psychology , Depression/therapyABSTRACT
Este artigo tem o escopo de mostrar a moclobemida, um inibidor reversível da MAOA apresenta um baixo perfil de interaçöes medicamentosas, principalmente no que tange à farmacodinâmica ocupando lugar de destaque na prática clínica para o tratamento de depressäo e alguns transtornos ansiosos